{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:06:46Z","timestamp":1791104806137,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.jaad.2013.06.011","type":"journal-article","created":{"date-parts":[[2013,8,16]],"date-time":"2013-08-16T21:18:04Z","timestamp":1376687884000},"page":"343.e1-343.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Primary cutaneous B-cell lymphomas"],"prefix":"10.1016","volume":"69","author":[{"given":"Andrea Lu\u00edsa","family":"Su\u00e1rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Querfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Pulitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia L.","family":"Myskowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2013.06.011_bib1","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","article-title":"European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas","volume":"112","author":"Senff","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.06.011_bib2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.6004\/jnccn.2011.0046","article-title":"Non-Hodgkin\u2019s lymphomas","volume":"9","author":"Zelenetz","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jaad.2013.06.011_bib3","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/archderm.143.12.1520","article-title":"Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification","volume":"143","author":"Senff","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.06.011_bib4","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2005.03.6285","article-title":"Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas","volume":"24","author":"Zinzani","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.06.011_bib5","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.06.011_bib6","series-title":"WHO classification of tumors of hematopiryic and lymphoid tisues","first-page":"227","article-title":"Primary cutaneous follicle center lymphoma","author":"Willemze","year":"2008"},{"key":"10.1016\/j.jaad.2013.06.011_bib7","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1200\/JCO.2006.09.6396","article-title":"Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers","volume":"25","author":"Senff","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.06.011_bib8","first-page":"49","article-title":"Dermatologic radiotherapy of primary cutaneous follicle center cell lymphoma","volume":"13","author":"Piccinno","year":"2003","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2013.06.011_bib9","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jaad.2010.06.059","article-title":"Clinicopathologic features of early lesions of primary cutaneous follicle center lymphoma, diffuse type: implications for early diagnosis and treatment","volume":"65","author":"Gulia","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.06.011_bib10","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3109\/10428194.2012.723707","article-title":"Radiotherapy in the management of localized primary cutaneous B-cell lymphoma","volume":"54","author":"Pashtan","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaad.2013.06.011_bib11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.clon.2012.02.007","article-title":"Skin lymphoma","volume":"24","author":"Morris","year":"2012","journal-title":"Clin Oncol"},{"key":"10.1016\/j.jaad.2013.06.011_bib12","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1177\/229255031101900208","article-title":"Primary cutaneous B-cell lymphoma: role of surgery","volume":"19","author":"Parbhakar","year":"2011","journal-title":"Can J Plast Surg"},{"key":"10.1016\/j.jaad.2013.06.011_bib13","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000241302","article-title":"New and experimental skin-directed therapies for cutaneous lymphomas","volume":"22","author":"Farkas","year":"2009","journal-title":"Skin Pharmacol Physiol"},{"key":"10.1016\/j.jaad.2013.06.011_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2133.2010.09798.x","article-title":"Intralesional corticosteroid therapy for primary cutaneous B-cell lymphoma","volume":"163","author":"Perry","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.06.011_bib15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0190-9622(97)80405-7","article-title":"Borrelia burgdorferi\u2013associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a","volume":"36","author":"Kutting","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.06.011_bib16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1468-3083.1999.tb00817.x","article-title":"Primary cutaneous B-cell lymphoma: treatment with low dose intralesional recombinant interferon-alpha 2A","volume":"12","author":"Rubegni","year":"1999","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2013.06.011_bib17","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/0959-8049(94)90101-5","article-title":"Complete remission of a primary cutaneous B cell lymphoma treated with intralesional recombinant interferon alpha-2a","volume":"30A","author":"Zenone","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2013.06.011_bib18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1473-3099(01)00095-0","article-title":"Topical immunomodulators\u2014progress towards treating inflammation, infection, and cancer","volume":"1","author":"Hengge","year":"2001","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jaad.2013.06.011_bib19","first-page":"391","article-title":"Topical imiquimod as treatment for different kinds of cutaneous lymphoma","volume":"16","author":"Coors","year":"2006","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2013.06.011_bib20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3816\/CLM.2008.n.015","article-title":"Primary cutaneous follicle center lymphoma associated with alopecia areata","volume":"8","author":"Richmond","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.jaad.2013.06.011_bib21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev.med.59.060906.220345","article-title":"A decade of rituximab: improving survival outcomes in non-Hodgkin\u2019s lymphoma","volume":"59","author":"Molina","year":"2008","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jaad.2013.06.011_bib22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/asheducation-2007.1.233","article-title":"Monoclonal antibodies for B-cell lymphomas: rituximab and beyond","author":"Bello","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jaad.2013.06.011_bib23","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/sj.leu.2402226","article-title":"CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells","volume":"15","author":"Selenko","year":"2001","journal-title":"Leukemia"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2013.06.011_bib24","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.3816\/CLM.2006.s.002","article-title":"Treatment of non-Hodgkin\u2019s lymphoma: a look over the past decade","volume":"7","author":"Coiffier","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.jaad.2013.06.011_bib25","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.06.011_bib26","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.06.011_bib27","first-page":"13","article-title":"Rituximab for follicular lymphoma","volume":"2","author":"Maloney","year":"2003","journal-title":"Curr Hematol Rep"},{"key":"10.1016\/j.jaad.2013.06.011_bib28","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jaad.2008.08.005","article-title":"Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab","volume":"59","author":"Morales","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.06.011_bib29","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/annonc\/mdn636","article-title":"Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients","volume":"20","author":"Valencak","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2013.06.011_bib30","first-page":"174","article-title":"Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma","volume":"67","author":"Pe\u00f1ate","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.06.011_bib31","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaad.2005.01.093","article-title":"Treatment of primary cutaneous B-cell lymphoma with rituximab","volume":"52","author":"Fink-Puches","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.06.011_bib32","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/107327481201900308","article-title":"Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management","volume":"19","author":"Sokol","year":"2012","journal-title":"Cancer Control"},{"key":"10.1016\/j.jaad.2013.06.011_bib33","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1080\/10428190802258923","article-title":"Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: first results of a prospective, monocentre study","volume":"49","author":"Maza","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"suppl 2","key":"10.1016\/j.jaad.2013.06.011_bib34","doi-asserted-by":"crossref","first-page":"ii72","DOI":"10.1093\/annonc\/mdn095","article-title":"Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"19","author":"Dummer","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2013.06.011_bib35","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1182\/blood-2004-01-0360","article-title":"Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas","volume":"104","author":"Dummer","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.06.011_bib36","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1525-1470.2008.00843.x","article-title":"Two pediatric cases of primary cutaneous B cell lymphoma and review of the literature","volume":"26","author":"Sharon","year":"2009","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2013.06.011_bib37","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1016\/j.jaad.2012.07.010","article-title":"Cryotherapy for primary cutaneous B-cell lymphoma","volume":"67","author":"Kennedy-Crispin","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.06.011_bib38","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/archderm.141.9.1139","article-title":"Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases","volume":"141","author":"Hoefnagel","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.06.011_bib39","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/00000478-200308000-00003","article-title":"Primary cutaneous marginal zone B-cell lymphoma. A molecular and clinicopathologic study of 24 Asian cases","volume":"27","author":"Li","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jaad.2013.06.011_bib40","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/10428190500399698","article-title":"Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma","volume":"47","author":"Cozzio","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaad.2013.06.011_bib41","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1600-0609.2006.00720.x","article-title":"Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab","volume":"77","author":"Kyrtsonis","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaad.2013.06.011_bib42","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1600-0560.1997.tb01318.x","article-title":"Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma","volume":"24","author":"Cerroni","year":"1997","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2013.06.011_bib43","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/00000478-200009000-00012","article-title":"Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland","volume":"24","author":"Goodlad","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jaad.2013.06.011_bib44","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1034\/j.1600-0560.2001.281002.x","article-title":"Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States","volume":"28","author":"Wood","year":"2001","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2013.06.011_bib45","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2796.2009.02083.x","article-title":"Infectious agents and lymphoma development: molecular and clinical aspects","volume":"265","author":"Ferreri","year":"2009","journal-title":"J Intern Med"},{"key":"10.1016\/j.jaad.2013.06.011_bib46","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1200\/JCO.2001.19.16.3602","article-title":"Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study","volume":"19","author":"Grange","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.06.011_bib47","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/archderm.143.9.1144","article-title":"Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases","volume":"143","author":"Grange","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.06.011_bib48","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/archderm.1996.03890350042008","article-title":"Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group","volume":"132","author":"Vermeer","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.06.011_bib49","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood-2003-08-2726","article-title":"Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas","volume":"103","author":"Grange","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.06.011_bib50","first-page":"753","article-title":"Rituximab for primary cutaneous diffuse large B-cell lymphoma-leg type","volume":"20","author":"Fenot","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2013.06.011_bib51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1600-0560.2007.00856.x","article-title":"Primary cutaneous spindle cell B-cell lymphoma with multiple figurate erythema-like manifestation","volume":"36","author":"Yun","year":"2009","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2013.06.011_bib52","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/mt.2010.52","article-title":"Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas","volume":"18","author":"Dummer","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaad.2013.06.011_bib53","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s12185-012-1198-3","article-title":"Diffuse large B cell lymphoma: molecular targeted therapy","volume":"96","author":"Roschewski","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jaad.2013.06.011_bib54","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2009.22.8254","article-title":"Investigational immunotherapeutics for B-cell malignancies","volume":"28","author":"Quintas-Cardama","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213006385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213006385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:27:01Z","timestamp":1759271221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962213006385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0190962213006385"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2013.06.011","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary cutaneous B-cell lymphomas","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2013.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}